Dive Brief:
- In response Vice-President Joe Biden's Cancer Moonshot Initiative, California-based precision medicine software company Syapse is teaming with two of the nation’s largest not-for-profit health systems - Intermountain Healthcare and Providence Health & Services - and major academic research center Stanford Cancer Institute to speed development of cancer precision medicines via a newly created consortium - Oncology Precision Network (OPN), according to an announcement.
- The consortium was created so that with the collaborating organizations can share aggregated clinical, molecular, and treatment data from 11 states, 79 hospitals, and 800 clinics using Syapse’s software platform to bring insights to cancer patients and physicians.
- When fully implemented, the organizations, which want the consortium to include other health systems later this year, predict OPN will impact 50,000 cancer patients annually have more than 1.5 million historical cancer cases. It is expected to launch with 100,000 datasets.
Dive Insight:
“This consortium exists because we all arrived at the same important conclusion: we need to collaborate across health systems to cure cancer,” Lincoln Nadauld, executive director of Intermountain Precision Genomics, said in a statement.
Jim Ford, head of clinical cancer genomics at the Stanford Cancer Institute, added: “By aggregating all of our real patient experiences, we will rapidly expand our ability to learn how to choose the best targeted treatments for our cancer patients base on the molecular profile of their tumor and our informatics based research.”